Development of&lt;sup&gt; 99m&lt;/sup&gt;Tc-radiolabeled nanosilica for targeted detection of HER2-positive breast cancer

Rainone, Paolo; Riva, Beatrice; Belloli, Sara; Sudati, Francesco; Ripamonti, M.; Verderio, Paolo; Colombo, Miriam; Colzani, Barbara; Gilardi, Maria Carla; Moresco, Rosa María; Prosperi, Davide

doi:10.2147/ijn.s129720

Cited by 35 publications

(26 citation statements)

References 49 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…(~7), which is also the case for the tumor-to-muscle ratio (~18) (Figure 6D ). A further interesting observation is that the non-targeted Fe 3 O 4 -DMSA- 99m Tc showed practically no decline in tumor uptake value from 4 to 24 h p.i., which leads us to the conclusion that the nanoparticle shell was stably labeled with 99m Tc, without being the subject of any degradation (Rainone et al, 2004 ). The decline in tumor uptake witnessed for Fe 3 O 4 -DMSA-SMCC-BCZM- 99m Tc may be attributed to in vivo clearance of the nanoconstruct, however even if this is the case, there is significant increase in the tumor/blood ratio from 4 to 24 h p.i.…”

Section: Resultsmentioning

confidence: 99%

A Novel Metal-Based Imaging Probe for Targeted Dual-Modality SPECT/MR Imaging of Angiogenesis

et al. 2018

View full text Add to dashboard Cite

Superparamagnetic iron oxide nanoparticles with well-integrated multimodality imaging properties have generated increasing research interest in the past decade, especially when it comes to the targeted imaging of tumors. Bevacizumab (BCZM) on the other hand is a well-known and widely applied monoclonal antibody recognizing VEGF-A, which is overexpressed in angiogenesis. The aim of this proof-of-concept study was to develop a dual-modality nanoplatform for in vivo targeted single photon computed emission tomography (SPECT) and magnetic resonance imaging (MRI) of tumor vascularization. Iron oxide nanoparticles (IONPs) have been coated with dimercaptosuccinic acid (DMSA), for consequent functionalization with the monoclonal antibody BCZM radiolabeled with 99mTc, via well-developed surface engineering. The IONPs were characterized based on their size distribution, hydrodynamic diameter and magnetic properties. In vitro cytotoxicity studies showed that our nanoconstruct does not cause toxic effects in normal and cancer cells. Fe3O4-DMSA-SMCC-BCZM-99mTc were successfully prepared at high radiochemical purity (>92%) and their stability in human serum and in PBS were demonstrated. In vitro cell binding studies showed the ability of the Fe3O4-DMSA-SMCC-BCZM-99mTc to bind to the VEGF-165 isoform overexpressed on M-165 tumor cells. The ex vivo biodistribution studies in M165 tumor-bearing SCID mice showed high uptake in liver, spleen, kidney and lungs. The Fe3O4-DMSA-SMCC-BCZM-99mTc demonstrated quick tumor accumulation starting at 8.9 ± 1.88%ID/g at 2 h p.i., slightly increasing at 4 h p.i. (16.21 ± 2.56%ID/g) and then decreasing at 24 h p.i. (6.01 ± 1.69%ID/g). The tumor-to-blood ratio reached a maximum at 24 h p.i. (~7), which is also the case for the tumor-to-muscle ratio (~18). Initial pilot imaging studies on an experimental gamma-camera and a clinical MR camera prove our hypothesis and demonstrate the potential of Fe3O4-DMSA-SMCC-BCZM-99mTc for targeted dual-modality imaging. Our findings indicate that Fe3O4-DMSA-SMCC-BCZM-99mTc IONPs could serve as an important diagnostic tool for biomedical imaging as well as a promising candidate for future theranostic applications in cancer.

show abstract

Section: Resultsmentioning

confidence: 99%

A Novel Metal-Based Imaging Probe for Targeted Dual-Modality SPECT/MR Imaging of Angiogenesis

et al. 2018

View full text Add to dashboard Cite

show abstract

“…Recently, a dual probe, 99m Tc-radiolabeled nanosilica system conjugated with a trastuzumab half-chain for aggressive HER2-positive breast cancer was developed by Rainone et al . [26] as a theranostic probe. Moreover, SPECT and MRI provided presurgical information such as the location of the sentinel lymph node.…”

Section: Positron Emission Tomographymentioning

confidence: 99%

Medical imaging modalities using nanoprobes for cancer diagnosis: A literature review on recent findings

Shahbazi‐Gahrouei

Khaniabadi

et al. 2019

J Res Med Sci

View full text Add to dashboard Cite

Medical imaging modalities are used for different types of cancer detection and diagnosis. Recently, there have been a lot of studies on developing novel nanoparticles as new medical imaging contrast agents for the early detection of cancer. The aim of this review article is to categorize the medical imaging modalities accompanying with using nanoparticles to improve potential imaging for cancer detection and hence valuable therapy in the future. Nowadays, nanoparticles are becoming potentially transformative tools for cancer detection for a wide range of imaging modalities, including computed tomography (CT), magnetic resonance imaging, single photon emission CT, positron emission tomography, ultrasound, and optical imaging. The study results seen in the recent literature provided and discussed the diagnostic performance of imaging modalities for cancer detections and their future directions. With knowledge of the correlation between the application of nanoparticles and medical imaging modalities and with the development of targeted contrast agents or nanoprobes, they may provide better cancer diagnosis in the future.

show abstract

“…Recently, a dual nanoprobe probe, 99m Tc-radiolabeled nanosilica system conjugated with a trastuzumab half-chain for aggressive HER2-positive breast cancer was developed by Rainone et al [60] as a theranostic probe. They developed 99mTc-radiolabeled nanosilica (SiNP) for targeted detection and for noninvasive detection, staging and potential treatment of HER2 positive breast cancer (HER2+ BC).…”

Section: Itron Emission Tomography (Pet)mentioning

confidence: 99%

A literature review on multimodality molecular imaging nanoprobes for cancer detection

Shahbazi‐Gahrouei

Khaniabadi

Shahbazi-Gahrouei

et al. 2019

Polish Journal of Medical Physics and Engineering

View full text Add to dashboard Cite

Molecular imaging techniques using nanoparticles have significant potential to be widely used for the detection of various types of cancers. Nowadays, there has been an increased focus on developing novel nanoprobes as molecular imaging contrast enhancement agents in nanobiomedicine. The purpose of this review article is to summarize the use of a variety of nanoprobes and their current achievements in accurate cancer imaging and effective treatment. Nanoprobes are rapidly becoming potential tools for cancer diagnosis by using novel molecular imaging modalities such as Ultrasound (US) imaging, Computerized Tomography (CT), Single Photon Emission Tomography (SPECT) and Positron Emission Tomography (PET), Magnetic Resonance Imaging (MRI), and Optical Imaging. These imaging modalities may facilitate earlier and more accurate diagnosis and staging the most of cancers.

show abstract

Development of<sup> 99m</sup>Tc-radiolabeled nanosilica for targeted detection of HER2-positive breast cancer

Cited by 35 publications

References 49 publications

A Novel Metal-Based Imaging Probe for Targeted Dual-Modality SPECT/MR Imaging of Angiogenesis

A Novel Metal-Based Imaging Probe for Targeted Dual-Modality SPECT/MR Imaging of Angiogenesis

Medical imaging modalities using nanoprobes for cancer diagnosis: A literature review on recent findings

A literature review on multimodality molecular imaging nanoprobes for cancer detection

Contact Info

Product

Resources

About